NPS Pharma Says 53% of Natpara-Treated Patients Achieved Primary Endpoint
October 07, 2013 at 08:09 AM EDT
NPS Pharmaceuticals, Inc. (NASDAQ: NPSP ), a biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide, yesterday presented findings from the